Study of a new drug for agitation in Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests an experimental medication, ITI-1284, to see if it can safely reduce agitation in people with Alzheimer's disease. Agitation can include restlessness, aggression, or irritability, and this drug aims to help manage those symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of Alzheimer's disease, confirmed by a blood test or a previous brain scan or spinal fluid test.
- You experience agitation that is not caused by other medications, medical conditions, or substance use.
- Your agitation is significant enough to score at least 4 on a standard assessment (NPI-AA) at two visits.
- Your overall dementia severity is moderate, as measured by a score between 6 and 24 on the MMSE-2 test.
- You do not have other major psychiatric conditions like schizophrenia, bipolar disorder, or unstable depression.
- You are not at high risk of suicide and have not attempted suicide in the past two years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether electroacupuncture (a type of acupuncture that uses mild electrical pulses) can help calm agitation in people with Alzheimer's disease. If you or your loved one has Alzheimer's and often feels restless or upset, this study may offer a new option.
This trial tests an experimental drug, ITI-1284, to see if it can safely reduce psychosis (hallucinations or delusions) in people with Alzheimer's disease. It may be an option for patients who have both Alzheimer's and related psychotic symptoms.
This trial tests two new drugs (EXV-802 and EXV-801) to see if they can safely reduce moderate to severe agitation in people with Alzheimer's dementia. If you or a loved one has Alzheimer's and has been experiencing significant agitation for at least two weeks, this study may be an option.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
This Phase 2 trial tests a study medicine to reduce “agitation” behaviors in people with Alzheimer’s dementia. You and your caregiver would complete required assessments and may need genetic and blood testing to check how the body handles the drug.
Hear when a new Agitation Associated With Alzheimer's Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.